Quite surprisingly, when the authors employed a hypothesis-driven approach with the selection of MYC as a candidate gene, they were unable to determine a role in predicting prognosis. MYC is well appreciated for its association with poorer prognosis in B cell lymphoma, albeit more so with gene rearrangement vs overexpression [6] , and thus reasonably evaluated. While it is naïve to presume similar roles for genes across all cancer types, the lack of an association with survival is still notable in this case given the central role of MYC in proliferation [7] . Nonetheless, persistently dismal survival rates in more aggressive disease underscores the plethora of data building on seminal studies, while many targets and pathways remain undiscovered. It is, of course, possible that the expression levels of these candidate genes are merely a consequence of complex upstream processes where intervention would be more effective.
Since Perou's 2000 initial report applying microarray technology to describe distinctive molecular subtypes based on gene expression signatures [8] , the field has evolved dramatically. Major advancements in sequencing technologies culminated in our authors' abilities to perform an exhaustive whole genome sequencing analysis that comprehensively spans the genome for any and all potential candidate genes. Coupled with a machine learning approach, this allows a large volume of data to be processed with extrapolated outcomes determined with statistically powered accuracy. The precision in which outcomes are estimated with mPS invariably sets it apart from currently accepted predictive scores; the closest comparator being Oncotype Dx.
The implications of utilizing AI approaches in cancer research are vast. Beyond prognostic studies, there is a more applicable role for predictive models. The authors of this study propose an integrated classification system, combining mPS and the clinical stage to stratify patients to seven classes. Extrapolation of data utilizing the METABRIC cohort further led to identification of groups determined to be unaffected by cytotoxic chemotherapy. In addition to prognostication, implementation of mPS may then serve to guide clinical management.
Shimizu and Nakayama offer a promising alternative to currently available tools for breast cancer prognostication, by highlighting a role for AI-based approaches. Future large-scale prospective studies will be integral moving forward.
